Core Insights - Dryden Gold Corp. has significantly expanded its discovery size at the Elora Gold System, tripling it within a year, indicating strong exploration success and potential for future growth [1]. Company Overview - Dryden Gold Corp. is publicly traded on TSXV under the ticker DRY, OTCQB as DRYGF, and FSE as X7W, focusing on gold exploration [4]. - The company is actively engaged in expanding its operations and has been featured in interviews that highlight its strategic vision and plans for the future [4]. Industry Context - CEO.CA serves as a leading platform for investors in junior mining and resource stocks, facilitating connections and knowledge sharing among millions of investors globally [2][6]. - The platform provides coverage of companies that are shaping the future of mining, showcasing insights from industry leaders [3].

Doubleview Gold Corp. Achieves a Major Breakthrough in Scandium Recovery from Copper Porphyry TailingsNovember 25, 2025 12:36 PM EST | Source: Doubleview Gold Corp.Vancouver, British Columbia--(Newsfile Corp. - November 25, 2025) - Doubleview Gold Corp. (TSXV: DBG) (OTCQB: DBLVF) (FSE: A1W038) (FSE: 1D4) ("Doubleview" or the "Company") is pleased to announce positive first-phase pre-optimization results from its two-year, novel scandium-focused metallurgical test program. These results confirm ...

Core Viewpoint - Phio Pharmaceuticals has completed enrollment in its Phase 1b clinical trial for its lead compound PH-762, which utilizes INTASYL gene silencing technology to target skin cancers [1][6]. Company Overview - Phio Pharmaceuticals Corp. is a clinical-stage siRNA biopharmaceutical company focused on developing therapeutics for cancer using its proprietary INTASYL® technology [1][6]. - The company's lead clinical program, PH-762, silences the PD-1 gene associated with various skin cancers, including cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma [1][6]. Clinical Trial Details - The Phase 1b trial aims to assess the safety and tolerability of intratumoral PH-762 in patients with Stages 1, 2, and 4 cutaneous squamous cell carcinoma, Stage 4 melanoma, and Stage 4 Merkel cell carcinoma [3]. - Patients in the trial receive four weekly injections of PH-762, with pathologic responses evaluated on day 36 post-initial injection [3]. Trial Progress and Results - A total of 18 patients have completed treatment across five dose-escalating cohorts, with significant pathologic responses observed: six patients achieved complete response (100% clearance), two had near complete response (>90% clearance), and two had partial response (>50% clearance) [4]. - No patients exhibited clinical progression of disease, and there were no dose-limiting toxicities or significant adverse effects reported [4][5]. Future Expectations - Pathology results for additional patients treated at the highest dose concentration are anticipated in Q1 2026 [1].

Core Viewpoint - Sorrento Resources Ltd. has clarified that the services provided by Independent Trading Group (ITG) are for market making, not media marketing, with services commencing on November 24, 2025, for a fee of CDN$5,500 per month [1]. Group 1: Market Making Services - ITG will enhance market depth, contribute to market liquidity, and add stability and efficiency to the market while acting as a liaison for the Company [2]. - ITG does not hold any interest in Sorrento Resources Ltd. or its securities, ensuring an arm's length relationship [2]. Group 2: Company Overview - Sorrento Resources Ltd. is focused on the acquisition, exploration, and development of mineral property assets in Canada, targeting precious metals, rare-earth elements, gold, and base metals [3]. - The Company is involved in specific projects such as the Bottom Brook REE Project, Rodgers Cove Gold, and the Harmsworth (VMS) project, all located in Newfoundland [3].

Core Insights - Canada One Mining Corp. has provided an exploration update following the Phase 2 exploration program at its 100% owned Copper Dome Project, highlighting significant findings of visible copper sulphide minerals, particularly in the Friday Creek zone [1][3]. Exploration Summary - The Phase 2 field program focused on historic MINFILE occurrences, with crews successfully visiting all documented locations and establishing 53 field stations with full metadata [4][6]. - A total of 29 rock samples were collected and submitted for analysis, with results expected in approximately four weeks [4][15]. - Early observations included the presence of chalcopyrite stringers, mineralized breccia cement, and bornite clots, indicating promising mineralization [5][6]. Geological Observations - The Friday Creek Zone exhibited strong potassic alteration and visible chalcopyrite and bornite mineralization, suggesting proximity to porphyry copper systems [7][9]. - Bornite, a copper-bearing sulphide mineral, was found across a significant area, indicating a potential high-temperature potassic zone and strong porphyry system potential near the surface [8][9]. - Alteration was mapped over a vertical extent of approximately 100 meters, with the strongest alteration intensity recorded at the valley bottom [9]. Future Plans - A follow-up field program is scheduled for Q2 2026, aimed at delineating alteration zonation patterns and understanding the structural controls on mineralization [14]. - Detailed petrographic and geochemical analyses will be conducted to refine the understanding of the relationship between observed hydrothermal alteration assemblages and the inferred porphyry center [14]. Project Context - The Copper Dome Project is located in the lower Quesnel Trough porphyry belt, adjacent to Hudbay Minerals Inc.'s Copper Mountain Mine, which has Proven and Probable Reserves of approximately 367 million tonnes at 0.25% Cu, 0.12 g/t Au, and 0.69 g/t Ag [16][17]. - The project benefits from excellent infrastructure, enabling year-round access and cost-efficient exploration in a stable jurisdiction [19].

Core Viewpoint - OS Therapies has received approval from the World Health Organization for the non-proprietary name 'daznelimgene lisbac' for its cancer immunotherapy product candidate OST-HER2, which is aimed at treating pulmonary metastatic osteosarcoma [1][2][3]. Company Overview - OS Therapies is a clinical stage oncology company specializing in listeria-based cancer immunotherapies, particularly for osteosarcoma and other solid tumors [3]. - The company is recognized as a leader in listeria-based cancer immunotherapies and is developing OST-HER2 to leverage the immune-stimulatory effects of Listeria bacteria [3]. Product Development - OST-HER2 has received multiple designations from regulatory authorities, including Rare Pediatric Disease Designation (RPDD) from the U.S. FDA and Fast-Track and Orphan Drug designations from both the U.S. FDA and European Medicines Agency [3]. - The company reported positive results from its Phase 2b clinical trial of OST-HER2, showing statistically significant benefits in the 12-month event-free survival (EFS) primary endpoint [3]. - A Biologics Licensing Application (BLA) for OST-HER2 is anticipated to be submitted to the U.S. FDA in early 2026, with the potential to receive a Priority Review Voucher if approved [3]. Future Plans - OS Therapies is on track to receive regulatory feedback from U.S., UK, and European authorities in December 2025, with plans to file for regulatory approvals starting in January 2026 [3]. - The company is also advancing its next-generation Antibody Drug Conjugate (ADC) and Drug Conjugates (DC) platform, known as tunable ADC (tADC), which utilizes proprietary technology for enhanced delivery of therapeutic payloads [4].

Core Insights - OneMeta Inc. has appointed three former technology leaders as Strategic Advisors, indicating a strong commitment to enhancing its strategic direction and operational capabilities [2][4] - The company specializes in AI-driven multilingual communication technologies, with its Verbum Suite designed to facilitate real-time multilingual interactions [3][8] Company Developments - The newly appointed advisors are Paul Jarman, former CEO of NICE CXone; Manoel Amorim, former CEO of Telefonica Brazil; and Bob Erickson, former CTO for Technology Strategy & Enterprise Data at U.S. Bank [2][4] - All three advisors have become shareholders in OneMeta, reflecting their confidence in the company's mission and long-term strategy [2] Advisor Contributions - Paul Jarman brings over two decades of experience in scaling SaaS and cloud innovations across large organizations, having led NICE CXone to global prominence [5] - Manoel Amorim has extensive leadership experience in telecommunications and finance, including roles that contributed to significant public offerings [6] - Bob Erickson's background in enterprise architecture and cloud transformation in regulated environments adds valuable insights to OneMeta's strategic planning [7] Industry Context - There is a growing demand for real-time multilingual communication solutions among enterprises worldwide, which OneMeta aims to address with its advanced technology [3][4]

Core Insights - NU E Power Corp. has successfully closed the acquisition of approximately 500 MW of hybrid power assets from ACT Mid Market Ltd., surpassing its target of 1 GW of secured global power capacity [1][8] - The company is positioned to meet the growing demand from AI hyperscalers, Bitcoin mining, and traditional grid customers, establishing itself as a rapidly scaling power platform [1][7] Acquisition Details - The acquired portfolio includes strategic hybrid sites across North America, Asia, South America, and Africa, with a flagship asset being the Dakhan Hybrid Energy & Data Complex in Mongolia [2] - The acquisition enhances NU E's diversified, multi-continental footprint, allowing it to supply reliable power regardless of end-use load [2] Leadership Changes - Broderick Gunning has been appointed as President, CEO, and Director, bringing two decades of experience in energy and digital infrastructure [3] - Frederick Stearman has been appointed Chief Technology Officer, while Bold Batsukh has been appointed Director - Asia, contributing regional expertise [4] Shareholder Changes - Following the acquisition, Brodie Gunning will control approximately 14% of the issued and outstanding voting securities of the company, increasing his stake significantly [10] - Samuel Kyler Hardy has resigned from the Board, with the company expressing gratitude for his contributions [5] Future Outlook - The company aims to accelerate towards its next target of 2 GW by 2027, indicating a strong growth trajectory [7] - NU E is described as a vertically integrated, load-agnostic power developer with over 1 GW of secured hybrid capacity across four continents [11]

Core Points - Grizzly Discoveries Inc. is conducting a private placement offering of Units and FT Units for gross proceeds of up to $1 million if fully subscribed [1][2] - The offering includes up to 8,333,333 Units and up to 25,000,000 FT Units, each priced at $0.03 [2] - Each Unit consists of one common share and one warrant, while each FT Unit consists of one common share and half a warrant [2] - The proceeds from the offering will primarily be used for mineral property exploration, totaling $750,000, along with other operational costs [3] Offering Details - The offering is available to qualified subscribers in Alberta, British Columbia, Ontario, and other jurisdictions as determined by the company [2] - The company may pay finders fees in cash, Units, and Warrants to registered broker dealers [4] - The offering is subject to acceptance by the TSX Venture Exchange [5] Company Overview - Grizzly Discoveries Inc. is a diversified Canadian mineral exploration company with a primary focus on developing approximately 72,700 hectares of precious and base metals properties in southeastern British Columbia [6] - The company is managed by a team with extensive experience in advancing exploration projects from early stages to feasibility [6]

Company Overview - Alliance Entertainment Holding Corporation (NASDAQ: AENT) is a leading distributor and omnichannel fulfillment partner in the entertainment and pop culture collectibles industry, offering over 340,000 unique SKUs across various categories including music, video, video games, licensed merchandise, and exclusive collectibles [1][4] - The company serves more than 35,000 retail and e-commerce storefronts, providing the largest selection of physical media in the market, including over 57,300 exclusive titles [4] Upcoming Event - Alliance Entertainment's management team will present at the Noble Capital Markets' 21st Annual Emerging Growth Equity Conference on December 2-3, 2025, in Boca Raton, Florida [1][3] - The conference is designed to enhance visibility and engagement for small and mid-cap companies through presentations and one-on-one investor meetings [2] Industry Context - NobleCon is an annual event that gathers public company executives, institutional investors, family offices, and industry leaders, focusing on emerging growth companies and investor access [2]